Loyal

Loyal is a veterinary biotechnology company developing the first FDA-approved longevity drugs for dogs, targeting the underlying biological processes of aging to help dogs live longer and healthier lives. Its lead drug candidate, LOY-002, is a once-daily pill targeting metabolic dysfunction in senior dogs (age 10+, 14+ lb) and has completed two of three major FDA requirements for conditional approval, with over 1,300 dogs enrolled in its STAY clinical trial across 70 veterinary clinics. The company also operates the Loyal Learning Hub, a free library of RACE-approved continuing education courses for veterinary teams.

‍